Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna stock slipped Wednesday after the company said its updated Covid vaccine can take on a highly mutated strain nicknamed "pirola."

Here's How Moderna's Updated Covid Shot Stacks Up Against Highly Mutated 'Pirola' Variant

Moderna Therapeutics Inc (NASDAQ:MRNA) has told investors that its revised Covid vaccine appears effective against the BA.2.86 subvariant, a highly mutated form of the coronavirus. Clinical trials revealed an 8.7-fold surge in neutralizing antibodies against this subvariant, which is closely monitored by global health agencies like the WHO and the CDC.

Moderna vaccine effective against latest Covid strain

The news comes amid concerns about rising cases in the U.S.

Moderna Stock Gains. Its Vaccine Is Effective Against New Covid Strain.

Moderna Inc. MRNA on Wednesday released clinical trial data indicating that its updated COVID-19 vaccination is effective against the BA.2.86 Pirola variant, which is being closely monitored by researchers due to concerns that it could more easily break through existing immunity. The new shot showed an 8.7 to 11-fold increase in neutralizing antibodies against BA.2.86 and other circulating variants, including the EG.5 Eris variant and FL.1.5.1, Moderna said in a release.

Moderna says updated COVID vaccine effective against BA.2.86 Pirola variant

Experts are worried the highly mutated variant, a relative of omicron formally called BA.2.86, could trigger a new wave of cases.

Moderna's Updated Covid Vaccine Is Effective Against Pirola Variant—As Concern Over New Strain Grows

Moderna on Wednesday said clinical trial data showed its updated COVID-19 vaccine will likely be effective against the highly-mutated BA.2.86 subvariant of the coronavirus that has raised fears of a resurgence of infections.

Moderna says updated COVID vaccine is effective against newer variant

Moderna, Pfizer and Novavax are slated to roll out new vaccines targeting XBB.1.5 within weeks, pending approvals from the FDA.

Moderna says updated Covid vaccine was effective against highly mutated BA.2.86 variant in trial

CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 vaccine for the fall 2023 season Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86, EG.5, and FL.1.5.1 variants With governments accelerating the timing of COVID-19 vaccination campaigns due to the potential risk of BA.2.86, Moderna has shared this data with regulators and is ready to supply its updated COVID-19 vaccine pending regulatory approval CAMBRIDGE, MA / ACCESSWIRE / September 6, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical trial data from its research assay confirm its updated COVID-19 vaccine, which is pending approval by the U.S. Food and Drug Administration for the fall 2023 vaccination season, generates an 8.7-fold increase in neutralizing antibodies in humans against BA.2.86 (Pirola), a variant under monitoring. The Centers for Disease Control (CDC) indicates that the highly mutated BA.2.86 variant may be more capable of causing infection in people who previously had COVID-19 or were vaccinated with previous vaccines, noting that updated COVID-19 vaccines may be effective in reducing severe disease and hospitalization.

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86

Novavax

Pfizer

The U.S. is reporting increases in positive coronavirus tests and in coronavirus hospitalizations. Pfizer, Moderna, and Novavax are readying their updated vaccines for the fall vaccination season.

Coronavirus Cases Are on the Rise -- Should You Buy Vaccine Stocks?

Bio-Rad Laboratories

CRISPR Therapeutics

Biotech stocks soared high during the COVID-19 pandemic, as they were our only hope for new drugs and vaccines to fight the virus. However, the biotech sector received little thanks from the market when the pandemic was over.

3 Beaten-Down Biotech Stocks Bound for a Bounce Back

We often think of tech stocks when we think of artificial intelligence investing. But other areas could benefit from this exciting technology.

Surprise! This Potential AI Winner Isn't a Tech Stock.

Johnson & Johnson

Merck

Judge Thomas Rose of the U.S. District Court for the Southern District of Ohio withdrew from a case that could block Medicare's drug price negotiation program.

Judge withdraws from Medicare drug price case after stock ownership is revealed

CAMBRIDGE, MA / ACCESSWIRE / August 30, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - R&D Day and Business Updates at 1:00 p.m. ET on Wednesday, September 13, 2023.

Moderna to Host Investor Event - R&D Day and Business Updates

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals said on Friday it plans to appeal a ruling by the U.S. District Court for the District of Delaware on two patents asserted against Moderna for the latter's COVID-19 vaccine Spikevax.

Alnylam to appeal ruling on patents related to Moderna's COVID vaccines

Biocept

Fresh Tracks Therapeutics Inc

Sonnet BioTherapeutics

TRACON Pharmaceuticals

Tenax Therapeutics

Windtree Therapeutics

Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.

7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole

The updated Covid vaccines from Pfizer, Moderna and Novavax still need green lights from the FDA and the CDC before they roll out to the public.

CDC expects new Covid vaccines from Pfizer, Moderna and Novavax to be available in mid-September

BioNTech SE

Drugmakers like Pfizer and Moderna tamped down expectations. Now, cases are increasing.

Covid Hospitalizations Jump. So Could Vaccine Demand.

Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fall.

U.S. Govt to Urge Citizens to Get New COVID-19 Shots

SHANGHAI , Aug. 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Interim Results. Business Highlights Collaboration agreement for zevor-cel commercialization in mainland China with Huadong Medicine.

CARsgen Announced 2023 Interim Results

Last week, Moderna and BioNTech partner Pfizer said their new COVID vaccines work against the current dominant strain of omicron growing across the U.S. Today, the Biden administration announced a campaign for citizens to get the new boosters this fall.

Why Moderna, BioNTech SE, and Novavax Surged Today

Novavax, Moderna, Pfizer and its partner BioNTech are slated to roll out new shots designed to target the omicron subvariant XBB.1.5 this fall.

Covid vaccine stocks jump as new variants emerge ahead of fall shot rollout

Moderna stock surged Monday after the biotech company inked a deal with China's Carsgen to study a new cancer vaccine regimen.

Moderna Surges On A Second, Unexpected Shot At The Cancer Vaccine Market

Moderna's COVID-19 vaccine was found to be over 95% effective at preventing illness, hospitalizations, and deaths. Experts predict another COVID-19 wave starting in September 2023, leading to increased revenue for Moderna. MRNA upgraded its sales guidance for the second half of 2023 to $6-8 billion, anticipating a spike in COVID-19 cases.

Moderna: Buy Before The Fall Covid-19 Wave

Moderna's (MRNA) updated monovalent COVID-19 vaccine generates a robust immune response against the dominating Eris variant and another rapidly spreading virus strain in a clinical study.

Moderna (MRNA) Updated COVID Jab Effective Against Eris Variant

The drugmakers designed their updated coronavirus shots to target the omicron subvariant XBB.1.5, which is slowly declining nationwide.

News for Moderna Stock (MRNA)